Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Open accessAbstract
Prostate cancer is one of the most prominent malignancies of elderly men in many Western countries including Europe and the United States with increasing trend worldwide. The growth of normal prostate as well as of prostate carcinoma cells depends on functional androgen receptor (AR) signaling. AR manifests the biological actions of androgens and its transcriptional activity is known to be influenced by signal transduction pathways. Here we show that Src, a nonreceptor tyrosine kinase, is overexpressed in androgen-independent prostate carcinoma C4-2 cells. Interestingly, the expression of Src was found to progressively increase (up to threefold) in transgenic adenocarcinoma of mouse prostate mice as a function of age and cancer progression. Blocking Src kinase function by a specific inhibitor, PP2, resulted in decreased AR transactivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific antigen (PSA). Consistent with this, overexpression of a functional Src mutant also led to a dramatic decrease in AR transactivation potential in a hormone-dependent manner. Interference with Src function in C4-2 cells led to decreased recruitment of AR on the target gene PSA enhancer and also resulted in the abrogation of hormone-dependent PSA transcript induction. Src inhibition also led to a dramatic decrease in the cell invasion in addition to decreasing the cellular growth. We suggest that targeting Src kinase could be an effective strategy to inhibit prostate cancer growth and metastasis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of C4-2 cells with the Src inhibitor protein phosphatase 2 in androgen-free conditions results in decreased activation of mouse mammary tumor virus and PSA luciferase reporters as well as reduced recruitment of the AR to the endogenous PSA gene enhancer region.
“Treatment of C4-2 cells with the Src inhibitor protein phosphatase 2 in androgen-free conditions results in a decreased activation of mouse mammary tumor virus and PSA luciferase reporters as well as reduced recruitment of the AR to the endogenous PSA gene enhancer region (44).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [44]
The citation lists haven’t been fetched yet
References 30 · Cited by 101
- Authors
- Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Eastern Finland (FI)
- Corresponding author
- Baniahmad, A
- Mukhtar, H
- Venue
- Oncogene
- Published
- 2008-01-28
- Volume
- 27
- Issue
- 25
- Pages
- 3596-3604
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC8445586
- OpenAlex
- W2005528673
- Cited by
- 101
- References
- 30
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 2 · 2022: 17 · 2021: 8 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 7 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 6
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA101039, R01CA 78809, R01CA078809, R01CA120451)
- National Institute of Diabetes and Digestive and Kidney Diseases (P50DK065303)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Keywords
- Src kinase, androgen receptor, castration-resistant prostate cancer, C4-2 cells, cell invasion, PP2 inhibitor, non-receptor tyrosine kinase, prostate cancer metastasis
- MeSH terms
- Androgens, Animals, Humans, Male, Mice, Transgenic, Models, Biological, Neoplasm Invasiveness, Prostatic Neoplasms, Receptors, Androgen, Transcription, Genetic, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Transgenes, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review